<DOC>
	<DOCNO>NCT01953211</DOCNO>
	<brief_summary>The degree suppression subsequent activation hypothalamic-pituitary-ovarian axis hormone-free interval combine oral contraceptive ( COC ) hormone user varies depend dose ethinyl estradiol formulation . This variation activation may associate different side effect hormone free interval . Progesterone ( P ) remain suppressed 6 COC regimen ( &lt; 1.8 ng/mL ) , indicate continuous contraceptive efficacy 7-day hormone free interval formulation study .</brief_summary>
	<brief_title>Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity</brief_title>
	<detailed_description />
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Healthy , reproductive age woman 18 35 year old , seek contraception general gynecology clinic LAC USC Medical Center w take one 6 possible monophasic COC formulation least 3 cycle prior enrollment regular menstrual cycle prior COCs Irregular bleed bilateral oophorectomy amenorrhea hormonesensitive cancer concurrent medication know interfere steroid metabolism ( i.e. , barbiturate , phenytoin , carbamazepine , ethosuximide , primidone , rifampin , tetracycline )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>